Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B

ter Borg M. J. , Hansen B. E. , Herrmann E., Zeuzem S., Cakaloglu Y. , Karayalcin S., ...Daha Fazla

ANTIVIRAL THERAPY, cilt.12, ss.1285-1294, 2007 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 12 Konu: 8
  • Basım Tarihi: 2007
  • Sayfa Sayıları: ss.1285-1294


Background: Pegylated interferon alpha 2b (PEG-IFN-alpha 2b) is effective for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, although its mechanism of action remains unclear. HBeAg loss is achieved in 36% of patients after one year of PEG-IFN-a2b treatment and combination therapy with lamivudine is not superior to PEG-IFN-alpha 2b monotherapy.